All Posts Tagged With: "HGSI"
(HGSI) Human Genome Sciences Analyst Still Neutral on Shares
We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $8.25.
Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical...
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a...
(HGSI) Human Genome Sciences – Bear of the Day
We are downgrading Human Genome Sciences Inc. (HGSI) to Underperform from Neutral following the disappointing third quarter 2011 results reported by the company. The company suffered a wider-than-expected...
(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00.
Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical...
(AAPL) 2011 Second Quarter Earnings Preview – Detailed
Earnings Preview 7/15/11
Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are...
(CMLS) Company News for March 11, 2011 – Corporate Summary
• Cumulus Media (NASDAQ:CMLS) reported that it has entered into a merger agreement to acquire all the outstanding common stock and warrants of Citadel Broadcasting Corp for $37 per share
• Starbucks (NASDAQ:
(ADSK) Company News for February 25, 2011 – Corporate Summary
• Iron Mountain (NYSE:IRM) reported Q4 EPS of $0.30, ex-items, slightly higher than the Zacks Consensus Estimate of $0.29.
• Newmont Mining (NYSE:NEM) reported...
(HGSI) Human Genome Sciences Earns FDA Panel Backing of Benlysta
Human Genome Sciences Inc. (HGSI) received a huge boost when its potential blockbuster candidate Benlysta received a positive recommendation from an advisory panel of the US Food and Drug Administration (FDA)....
(HGSI) Human Genome Sciences Reports Narrower Than Expected Earnings Loss
Human Genome Sciences Inc.’s (HGSI) third quarter 2010 loss of 22 cents per share was narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 32 cents. The narrower loss...
(HGSI) Human Genome Sciences Earns Priority Review for Benlysta
Human Genome Sciences, Inc. (HGSI) received a huge boost when its potential blockbuster drug candidate Benlysta was granted priority review status by the US Food and Drug Administration (FDA). Benlysta, co-developed...
(HGSI) Human Genome Sciences Seeks Lupus Drug FDA Approval
Human Genome Sciences Inc. (HGSI) recently submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking marketing approval for its potential blockbuster lupus drug...
(HGSI) Human Genome Sciences Seeks European Approval For Lupus Drug
Human Genome Sciences Inc. (HGSI) recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking marketing approval for its potential blockbuster lupus drug...
(HGSI) Human Genome Sciences’ Earnings Scorecard
Human Genome Sciences, Inc.’s (HGSI) first quarter 2010 net loss of 26 cents per share was wider than the Zacks Consensus Estimate of a loss of 20 cents. The company earned 56 cents in the year-ago quarter.
We...
(HGSI) Human Genome Sciences Reports Wider-Than-Expected Loss
Human Genome Sciences Inc’s (HGSI) first quarter 2010 net loss of 26 cents per share was wider than the Zacks Consensus Estimate of 20 cents. The company earned 56 cents per share (excluding special...
(HGSI) Human Genome Sciences Announces Bad News for Lupus Candidate
Recently, Human Genome Sciences, Inc. (HGSI) announced that its potential blockbuster lupus drug candidate Benlysta (belimumab) failed to meet its secondary goals in a late-stage trial BLISS-76.
Human...
(HGSI) Human Genome Sciences Gets Setback From Partner Novartis AG
Recently, Human Genome Sciences Inc. (HGSI) received a setback when the Marketing Authorization Application (MAA) for its hepatitis C candidate Joulferon (albinterferon alfa-2b) was withdrawn by its partner...
(HGSI) Human Genome Sciences Releases Encouraging Data on Zalbin
Recently, Human Genome Sciences Inc. (HGSI) announced interim results on hepatitis C candidate Zalbin from a mid-stage study. The study evaluated the safety and efficacy of Zalbin. The results revealed that...
(HGSI) Human Genome Sciences Joins Forces With Swedish To Commercialize New Drugs
Human Genome Sciences, Inc. (HGSI) and BioInvent International AB, a Swedish pharmaceutical research company, have joined forces to discover, develop and commercialize therapeutic monoclonal antibodies that...
(HGSI) Human Genome Sciences Reports Lower Fourth Quarter Loss
Human Genome Sciences, Inc. (HGSI) reported fourth quarter 2009 net loss of $9.7 million or 6 cents per share, narrower than the Zacks Consensus Estimate of 9 cents and the year-ago loss of $61.9 million...
(HGSI) Human Genome Sciences Pipeline Bigger than Earnings
Human Genome Sciences, Inc. (HGSI) is expected to report fourth quarter as well as fiscal 2009 results shortly. We expect that the company will report a loss of 10 cents per share for the fourth quarter of...
(DNDN) These Biotech Stocks Are Just What the Doctor Ordered
by Louise Harris, Investment U Research
Thursday, January 28, 2010
They say that one in every nine women will get breast cancer.
It’s a staggering statistic, just like the equally frightening claim that one in four people will end up with some...
(HGSI) Human Genome Sciences to Seek Drug Approval in Second Quarter
Human Genome Sciences Inc. (HGSI) announced recently that it intends to seek approval for its potential blockbuster lupus drug candidate Benlysta during the second quarter of 2010 in the United States and...
(HGSI) Human Genome Sciences Seeks Approval For Hepatitis C Treatment
Human Genome Sciences, Inc. (HGSI) recently announced the submission of a Marketing Authorization Application, [MAA], to the European Medicines Agency (EMEA) seeking marketing approval of Joulferon (albinterferon...
(HGSI) Human Genome Sciences to Sell 12.5 Million Shares
Human Genome Sciences Inc. (HGSI) announced that it intends to sell up to 12.5 million shares to raise money for the development of its potential blockbuster lupus drug Benlysta and other business activities.
The...
(HGSI) Human Genome Sciences Begins Trial
Recently, Human Genome Sciences, Inc. (HGSI) and Aegera Therapeutics announced the initiation of dosing in a phase I clinical trial to evaluate the safety and tolerability of its lead inhibitor-of-apoptosis...
(HGSI) Human Genome Sciences’ ABthrax Faces FDA Delay
Recently, Human Genome Sciences Inc. (HGSI) announced that the U.S. Food and Drug Administration (FDA) delayed the approval of ABthrax (raxibacumab), the company’s candidate for anthrax treatment, asking...
(HGSI) Human Genome Sciences Reports Lower Q3 Loss
Human Genome Sciences, Inc. (HGSI) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a...
(HGSI) Human Genome Sciences Gets FDA Panel Request for ABthrax Data
A panel of experts of the US Food and Drug Administration (FDA) has recently asked for additional data to judge the efficacy of Human Genome Sciences Inc.’s (HGSI) anthrax infection treatment ABthrax (raxibacumab)...
(HGSI) Human Genome Sciences Drug Under FDA Review
Recently, Human Genome Sciences Inc. (HGSI) suffered a setback when the US Food and Drug Administration (FDA) questioned the efficacy of its drug ABthrax (raxibacumab), meant for treating anthrax infection.
The...